Pharmacology, Toxicology and Pharmaceutical Science
Delirium
100%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
50%
Diseases
19%
Cohort Study
19%
Placebo
18%
Randomized Clinical Trial
18%
Prospective Cohort Study
16%
Coronavirinae
16%
Melanoma
16%
Clonidine
16%
Coma
15%
Nivolumab
8%
Pembrolizumab
8%
Trametinib
8%
Dabrafenib
8%
Structure Activity Relationship
6%
Adverse Event
6%
Hospital Mortality
5%
Immune Checkpoint Inhibitor
5%
Medicine and Dentistry
Delirium
66%
Cohort Analysis
17%
Cost-Effectiveness Analysis
16%
COVID-19
16%
Adjuvant Therapy
16%
Haloperidol
16%
Randomized Clinical Trial
16%
Melanoma
16%
Post-Hoc Analysis
16%
Health Care Cost
14%
Coma
11%
Intensive Care Unit
9%
Placebo
8%
Quality Adjusted Life Year
6%
Nivolumab
6%
Dabrafenib
6%
Pembrolizumab
6%
Trametinib
6%
Hospital Mortality
5%
Nursing and Health Professions
Delirium
66%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
33%
Intensive Care Unit
20%
Cohort Analysis
18%
Systematic Review with Meta-Analysis
16%
Clonidine
16%
Prospective Cohort Study
16%
Post Hoc Analysis
16%
Coma
10%
Placebo
10%
Adverse Event
6%
Hospital Mortality
5%
